Pavmed Stock Price, News & Analysis

Lucid Diagnostics (Nasdaq: LUCD) has begun high-volume production of its EsoCheck® Esophageal Cell Collection Devices at Coastline International, significantly reducing production costs by approximately 60%. This transition enhances manufacturing capacity to 20,000 units annually, with potential scalability to over one million units. The EsoCheck device is vital for the EsoGuard® Esophageal DNA Test, aimed at early detection of esophageal precancer in GERD patients. This strategic move underscores Lucid's commitment to improving cancer screening and prevention.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will host a business update conference call on November 15, 2022, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will share insights on the company’s growth strategy and third-quarter 2022 financial results. The call can be accessed via telephone or live webcast on their investor relations website. PAVmed is a commercial-stage medical technology company, operational in diagnostics and digital health, with subsidiaries like Lucid Diagnostics focusing on cancer prevention.

Lucid Diagnostics Inc. (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, will host a conference call on November 14, 2022, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will discuss a business update and third-quarter financial results. Investors can join the call via telephone or webcast. Lucid focuses on early cancer detection in GERD patients with its EsoGuard Esophageal DNA Test and EsoCheck device, both crucial for preventing esophageal cancer.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has announced that its Chairman and CEO, Lishan Aklog, M.D., will hold one-on-one investor meetings at the 6th Annual Best Ideas Growth (BIG6) Conference on September 14, 2022 and the A.G.P. Virtual MedTech Conference on September 21, 2022. PAVmed operates in the medical device, diagnostics, and digital health sectors, with subsidiaries including Lucid Diagnostics Inc. (Nasdaq: LUCD) and Veris Health Inc.. Lucid specializes in cancer prevention diagnostics, while PAVmed’s product pipeline includes various innovative medical devices.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) reports significant growth in Lucid Diagnostics' EsoGuard test volume, achieving a 60% sequential increase in Q2 2022 with 850 tests. This marks a 300% annual increase. Lucid plans to launch its Veris Health Cancer Care Platform this year, while expanding its sales team and regional presence. However, financial results reflect challenges, including a GAAP net loss of approximately $25.5 million and no recorded EsoGuard revenues. Cash reserves decreased to $65.2 million. The company continues developing its product pipeline with FDA submissions expected in 2023.

Lucid Diagnostics Inc. (Nasdaq: LUCD) reported a substantial increase in EsoGuard test volume, achieving 60% growth quarter-over-quarter and over 300% year-over-year. The company’s CLIA-Certified LucidDx Labs is now fully operational and billing independently. Operating expenses for Q2 2022 were approximately $14.6 million resulting in a net loss of $14.6 million or $(0.41) per share. Despite no recognized revenue for the 850 tests processed, Lucid continues to expand its sales team and has initiated new Lucid Test Centers in key metropolitan areas.

Lucid Diagnostics has expanded its services by launching four new Lucid Test Centers in Orange County, Dallas-Fort Worth, Palm Beach County, and Columbus, Ohio. These centers will offer a non-invasive test to detect esophageal precancer in patients with chronic heartburn, utilizing the EsoGuard DNA Esophageal Test and EsoCheck device. With a projected opening of nine new centers this year, Lucid aims to enhance its national footprint and accessibility to early cancer detection. The company emphasizes that early detection can significantly reduce the risk of progressing to fatal esophageal cancer.

Lucid Diagnostics Inc. (NASDAQ: LUCD) announced significant updates to its esophageal precancer screening guidelines, as endorsed by the American Gastroenterological Association (AGA). These updates expand the target population for EsoGuard screening, now including at-risk patients without chronic heartburn symptoms. The update emphasizes non-invasive methods, highlighting EsoCheck as a viable alternative to traditional endoscopy. The AGA's endorsement comes amid rising esophageal cancer rates, furthering the need for accessible screening tools.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) will hold a business update conference call on August 16, 2022, at 4:30 PM EDT. CEO Lishan Aklog will review company operations and growth strategies, while CFO Dennis McGrath will present the second-quarter financial results. The call can be accessed via phone or webcast through the company's website. PAVmed is a diversified medical technology company, with its subsidiary Lucid Diagnostics focusing on cancer prevention diagnostics with products like EsoGuard® and EsoCheck®.